PubMed:23889885 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":170},"obj":"Sentence"},{"id":"T2","span":{"begin":171,"end":182},"obj":"Sentence"},{"id":"T3","span":{"begin":183,"end":336},"obj":"Sentence"},{"id":"T4","span":{"begin":337,"end":472},"obj":"Sentence"},{"id":"T5","span":{"begin":473,"end":481},"obj":"Sentence"},{"id":"T6","span":{"begin":482,"end":682},"obj":"Sentence"},{"id":"T7","span":{"begin":683,"end":921},"obj":"Sentence"},{"id":"T8","span":{"begin":922,"end":930},"obj":"Sentence"},{"id":"T9","span":{"begin":931,"end":1076},"obj":"Sentence"},{"id":"T10","span":{"begin":1077,"end":1185},"obj":"Sentence"},{"id":"T11","span":{"begin":1186,"end":1356},"obj":"Sentence"},{"id":"T12","span":{"begin":1357,"end":1521},"obj":"Sentence"},{"id":"T13","span":{"begin":1522,"end":1597},"obj":"Sentence"},{"id":"T14","span":{"begin":1598,"end":1666},"obj":"Sentence"},{"id":"T15","span":{"begin":1667,"end":1706},"obj":"Sentence"},{"id":"T16","span":{"begin":1707,"end":1848},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":170},"obj":"Sentence"},{"id":"T2","span":{"begin":171,"end":182},"obj":"Sentence"},{"id":"T3","span":{"begin":183,"end":336},"obj":"Sentence"},{"id":"T4","span":{"begin":337,"end":472},"obj":"Sentence"},{"id":"T5","span":{"begin":473,"end":481},"obj":"Sentence"},{"id":"T6","span":{"begin":482,"end":682},"obj":"Sentence"},{"id":"T7","span":{"begin":683,"end":921},"obj":"Sentence"},{"id":"T8","span":{"begin":922,"end":930},"obj":"Sentence"},{"id":"T9","span":{"begin":931,"end":1076},"obj":"Sentence"},{"id":"T10","span":{"begin":1077,"end":1185},"obj":"Sentence"},{"id":"T11","span":{"begin":1186,"end":1356},"obj":"Sentence"},{"id":"T12","span":{"begin":1357,"end":1521},"obj":"Sentence"},{"id":"T13","span":{"begin":1522,"end":1597},"obj":"Sentence"},{"id":"T14","span":{"begin":1598,"end":1666},"obj":"Sentence"},{"id":"T15","span":{"begin":1667,"end":1706},"obj":"Sentence"},{"id":"T16","span":{"begin":1707,"end":1848},"obj":"Sentence"}],"text":"Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial.\nBACKGROUND: Acute ankle sprains are common and activity limiting injuries, and topical diclofenac gel has proven efficacy in alleviating pain and restoring function. This trial aimed to compare a topical natural agent, Traumeel with topical diclofenac gel (1%) in the management of acute ankle sprain.\nMETHODS: This prospective, multicentre, randomised, blinded, active-control and non-inferiority study involved 449 physically active adults sustaining unilateral grade 1 or 2 ankle sprain within the past 24 h. Participants were randomised to receive 2 g of Traumeel ointment (T-O) (n = 152) or Traumeel gel (T-G) (n = 150) or diclofenac gel (D-G) (n = 147), administered topically to the ankle three times a day for 14 days, with 6-weeks follow up.\nRESULTS: Day 7 median percentage reductions in Visual Analogue Scale pain score were 60.6%, 71.1% and 68.9% for the T-O, T-G and D-G groups, respectively. Total pain relief was reported by 12 (8.5%), 7 (5.0%) and 8 (5.9%) participants in each group, respectively. Median improvements in Foot and Ankle Ability Measure Activities of Daily Living subscale score were 26.2, 26.2 and 25.0 points for T-O, T-G and D-G groups, respectively. Mann-Whitney effect sizes and lower bound confidence intervals demonstrated non-inferiority of Traumeel vs. diclofenac for reducing pain and functional improvement. At 6 weeks, participants reported total pain relief and normal functioning. Adverse events (n = 43) were reported by 31/447 participants (6.9%). Treatments were equally well tolerated.\nCONCLUSIONS: T-O and T-G decreased pain and improved joint function to the same extent as D-G in acute ankle sprain, and were well tolerated."}

{"project":"Allie","denotations":[{"id":"SS1_23889885_6_0","span":{"begin":730,"end":747},"obj":"expanded"},{"id":"SS2_23889885_6_0","span":{"begin":749,"end":752},"obj":"abbr"},{"id":"SS1_23889885_6_1","span":{"begin":767,"end":779},"obj":"expanded"},{"id":"SS2_23889885_6_1","span":{"begin":781,"end":784},"obj":"abbr"},{"id":"SS1_23889885_6_2","span":{"begin":799,"end":813},"obj":"expanded"},{"id":"SS2_23889885_6_2","span":{"begin":815,"end":818},"obj":"abbr"}],"relations":[{"id":"AE1_23889885_6_0","pred":"abbreviatedTo","subj":"SS1_23889885_6_0","obj":"SS2_23889885_6_0"},{"id":"AE1_23889885_6_1","pred":"abbreviatedTo","subj":"SS1_23889885_6_1","obj":"SS2_23889885_6_1"},{"id":"AE1_23889885_6_2","pred":"abbreviatedTo","subj":"SS1_23889885_6_2","obj":"SS2_23889885_6_2"}],"text":"Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial.\nBACKGROUND: Acute ankle sprains are common and activity limiting injuries, and topical diclofenac gel has proven efficacy in alleviating pain and restoring function. This trial aimed to compare a topical natural agent, Traumeel with topical diclofenac gel (1%) in the management of acute ankle sprain.\nMETHODS: This prospective, multicentre, randomised, blinded, active-control and non-inferiority study involved 449 physically active adults sustaining unilateral grade 1 or 2 ankle sprain within the past 24 h. Participants were randomised to receive 2 g of Traumeel ointment (T-O) (n = 152) or Traumeel gel (T-G) (n = 150) or diclofenac gel (D-G) (n = 147), administered topically to the ankle three times a day for 14 days, with 6-weeks follow up.\nRESULTS: Day 7 median percentage reductions in Visual Analogue Scale pain score were 60.6%, 71.1% and 68.9% for the T-O, T-G and D-G groups, respectively. Total pain relief was reported by 12 (8.5%), 7 (5.0%) and 8 (5.9%) participants in each group, respectively. Median improvements in Foot and Ankle Ability Measure Activities of Daily Living subscale score were 26.2, 26.2 and 25.0 points for T-O, T-G and D-G groups, respectively. Mann-Whitney effect sizes and lower bound confidence intervals demonstrated non-inferiority of Traumeel vs. diclofenac for reducing pain and functional improvement. At 6 weeks, participants reported total pain relief and normal functioning. Adverse events (n = 43) were reported by 31/447 participants (6.9%). Treatments were equally well tolerated.\nCONCLUSIONS: T-O and T-G decreased pain and improved joint function to the same extent as D-G in acute ankle sprain, and were well tolerated."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":308,"end":312},"obj":"HP_0012531"}],"text":"Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial.\nBACKGROUND: Acute ankle sprains are common and activity limiting injuries, and topical diclofenac gel has proven efficacy in alleviating pain and restoring function. This trial aimed to compare a topical natural agent, Traumeel with topical diclofenac gel (1%) in the management of acute ankle sprain.\nMETHODS: This prospective, multicentre, randomised, blinded, active-control and non-inferiority study involved 449 physically active adults sustaining unilateral grade 1 or 2 ankle sprain within the past 24 h. Participants were randomised to receive 2 g of Traumeel ointment (T-O) (n = 152) or Traumeel gel (T-G) (n = 150) or diclofenac gel (D-G) (n = 147), administered topically to the ankle three times a day for 14 days, with 6-weeks follow up.\nRESULTS: Day 7 median percentage reductions in Visual Analogue Scale pain score were 60.6%, 71.1% and 68.9% for the T-O, T-G and D-G groups, respectively. Total pain relief was reported by 12 (8.5%), 7 (5.0%) and 8 (5.9%) participants in each group, respectively. Median improvements in Foot and Ankle Ability Measure Activities of Daily Living subscale score were 26.2, 26.2 and 25.0 points for T-O, T-G and D-G groups, respectively. Mann-Whitney effect sizes and lower bound confidence intervals demonstrated non-inferiority of Traumeel vs. diclofenac for reducing pain and functional improvement. At 6 weeks, participants reported total pain relief and normal functioning. Adverse events (n = 43) were reported by 31/447 participants (6.9%). Treatments were equally well tolerated.\nCONCLUSIONS: T-O and T-G decreased pain and improved joint function to the same extent as D-G in acute ankle sprain, and were well tolerated."}

{"project":"maxiaofeng52_800_3","denotations":[{"id":"T1","span":{"begin":0,"end":8},"obj":"CI"},{"id":"T10","span":{"begin":799,"end":809},"obj":"CI"},{"id":"T11","span":{"begin":77,"end":95},"obj":"DP"},{"id":"T12","span":{"begin":183,"end":202},"obj":"DP"},{"id":"T13","span":{"begin":453,"end":471},"obj":"DP"},{"id":"T14","span":{"begin":1804,"end":1822},"obj":"DP"},{"id":"T2","span":{"begin":13,"end":23},"obj":"CI"},{"id":"T3","span":{"begin":390,"end":398},"obj":"CI"},{"id":"T4","span":{"begin":730,"end":738},"obj":"CI"},{"id":"T5","span":{"begin":767,"end":775},"obj":"CI"},{"id":"T6","span":{"begin":1452,"end":1460},"obj":"CI"},{"id":"T7","span":{"begin":1465,"end":1475},"obj":"CI"},{"id":"T8","span":{"begin":412,"end":422},"obj":"CI"},{"id":"T9","span":{"begin":258,"end":268},"obj":"CI"},{"id":"T15","span":{"begin":749,"end":750},"obj":"CI"},{"id":"T16","span":{"begin":781,"end":782},"obj":"CI"},{"id":"T17","span":{"begin":815,"end":816},"obj":"CI"},{"id":"T18","span":{"begin":1051,"end":1052},"obj":"CI"},{"id":"T19","span":{"begin":1331,"end":1332},"obj":"CI"},{"id":"T20","span":{"begin":1797,"end":1798},"obj":"CI"},{"id":"T21","span":{"begin":1038,"end":1039},"obj":"CI"},{"id":"T22","span":{"begin":1043,"end":1044},"obj":"CI"},{"id":"T23","span":{"begin":1318,"end":1319},"obj":"CI"},{"id":"T24","span":{"begin":1323,"end":1324},"obj":"CI"},{"id":"T25","span":{"begin":1720,"end":1721},"obj":"CI"},{"id":"T26","span":{"begin":1728,"end":1729},"obj":"CI"},{"id":"T27","span":{"begin":654,"end":660},"obj":"DP"}],"text":"Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial.\nBACKGROUND: Acute ankle sprains are common and activity limiting injuries, and topical diclofenac gel has proven efficacy in alleviating pain and restoring function. This trial aimed to compare a topical natural agent, Traumeel with topical diclofenac gel (1%) in the management of acute ankle sprain.\nMETHODS: This prospective, multicentre, randomised, blinded, active-control and non-inferiority study involved 449 physically active adults sustaining unilateral grade 1 or 2 ankle sprain within the past 24 h. Participants were randomised to receive 2 g of Traumeel ointment (T-O) (n = 152) or Traumeel gel (T-G) (n = 150) or diclofenac gel (D-G) (n = 147), administered topically to the ankle three times a day for 14 days, with 6-weeks follow up.\nRESULTS: Day 7 median percentage reductions in Visual Analogue Scale pain score were 60.6%, 71.1% and 68.9% for the T-O, T-G and D-G groups, respectively. Total pain relief was reported by 12 (8.5%), 7 (5.0%) and 8 (5.9%) participants in each group, respectively. Median improvements in Foot and Ankle Ability Measure Activities of Daily Living subscale score were 26.2, 26.2 and 25.0 points for T-O, T-G and D-G groups, respectively. Mann-Whitney effect sizes and lower bound confidence intervals demonstrated non-inferiority of Traumeel vs. diclofenac for reducing pain and functional improvement. At 6 weeks, participants reported total pain relief and normal functioning. Adverse events (n = 43) were reported by 31/447 participants (6.9%). Treatments were equally well tolerated.\nCONCLUSIONS: T-O and T-G decreased pain and improved joint function to the same extent as D-G in acute ankle sprain, and were well tolerated."}

{"project":"wangzhuo19_800_3","denotations":[{"id":"T1","span":{"begin":13,"end":23},"obj":"CI"},{"id":"T10","span":{"begin":1452,"end":1460},"obj":"CI"},{"id":"T11","span":{"begin":749,"end":750},"obj":"CI"},{"id":"T12","span":{"begin":781,"end":782},"obj":"CI"},{"id":"T13","span":{"begin":1038,"end":1039},"obj":"CI"},{"id":"T14","span":{"begin":1043,"end":1044},"obj":"CI"},{"id":"T15","span":{"begin":1318,"end":1319},"obj":"CI"},{"id":"T16","span":{"begin":1323,"end":1324},"obj":"CI"},{"id":"T17","span":{"begin":1720,"end":1721},"obj":"CI"},{"id":"T18","span":{"begin":1728,"end":1729},"obj":"CI"},{"id":"T19","span":{"begin":815,"end":816},"obj":"CI"},{"id":"T2","span":{"begin":258,"end":268},"obj":"CI"},{"id":"T20","span":{"begin":1051,"end":1052},"obj":"CI"},{"id":"T21","span":{"begin":1331,"end":1332},"obj":"CI"},{"id":"T22","span":{"begin":1797,"end":1798},"obj":"CI"},{"id":"T23","span":{"begin":77,"end":95},"obj":"DP"},{"id":"T24","span":{"begin":453,"end":471},"obj":"DP"},{"id":"T25","span":{"begin":1804,"end":1822},"obj":"DP"},{"id":"T26","span":{"begin":654,"end":660},"obj":"DP"},{"id":"T3","span":{"begin":412,"end":422},"obj":"CI"},{"id":"T4","span":{"begin":799,"end":809},"obj":"CI"},{"id":"T5","span":{"begin":1465,"end":1475},"obj":"CI"},{"id":"T6","span":{"begin":0,"end":8},"obj":"CI"},{"id":"T7","span":{"begin":390,"end":398},"obj":"CI"},{"id":"T8","span":{"begin":730,"end":738},"obj":"CI"},{"id":"T9","span":{"begin":767,"end":775},"obj":"CI"},{"id":"T27","span":{"begin":183,"end":202},"obj":"DP"}],"text":"Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial.\nBACKGROUND: Acute ankle sprains are common and activity limiting injuries, and topical diclofenac gel has proven efficacy in alleviating pain and restoring function. This trial aimed to compare a topical natural agent, Traumeel with topical diclofenac gel (1%) in the management of acute ankle sprain.\nMETHODS: This prospective, multicentre, randomised, blinded, active-control and non-inferiority study involved 449 physically active adults sustaining unilateral grade 1 or 2 ankle sprain within the past 24 h. Participants were randomised to receive 2 g of Traumeel ointment (T-O) (n = 152) or Traumeel gel (T-G) (n = 150) or diclofenac gel (D-G) (n = 147), administered topically to the ankle three times a day for 14 days, with 6-weeks follow up.\nRESULTS: Day 7 median percentage reductions in Visual Analogue Scale pain score were 60.6%, 71.1% and 68.9% for the T-O, T-G and D-G groups, respectively. Total pain relief was reported by 12 (8.5%), 7 (5.0%) and 8 (5.9%) participants in each group, respectively. Median improvements in Foot and Ankle Ability Measure Activities of Daily Living subscale score were 26.2, 26.2 and 25.0 points for T-O, T-G and D-G groups, respectively. Mann-Whitney effect sizes and lower bound confidence intervals demonstrated non-inferiority of Traumeel vs. diclofenac for reducing pain and functional improvement. At 6 weeks, participants reported total pain relief and normal functioning. Adverse events (n = 43) were reported by 31/447 participants (6.9%). Treatments were equally well tolerated.\nCONCLUSIONS: T-O and T-G decreased pain and improved joint function to the same extent as D-G in acute ankle sprain, and were well tolerated."}